GSK to appeal ruling

GlaxoSmithKline PLC
13 March 2002



               Federal Court Rules in AUGMENTIN Patent Challenge

           GSK to Appeal Ruling on Patents Expiring in 2017 and 2018


PHILADELPHIA, March 13, 2002 -- GlaxoSmithKline (NYSE: GSK) today announced that
a federal judge in the United States District Court for the Eastern District of
Virginia has ruled on a summary judgment motion filed by Teva Pharmaceuticals
(Teva), relating to the validity of three of GSK's patents in the United States
covering its antibiotic product AUGMENTIN. In the summary judgment ruling, the
court ruled in Teva's favor that three GSK patents expiring in 2017 were
invalid.

On December 14, 2001, the same judge ruled on two other GSK patents covering
AUGMENTIN. The court ruled that a patent expiring in 2018 was invalid. However,
on that same date, the court ruled that a patent expiring in December, 2002 was
valid.

GSK believes its patents covering AUGMENTIN are valid and expects to appeal
these rulings. A decision on appeal would normally take twelve to eighteen
months from the filing of the appeal.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.

S M Bicknell

Company Secretary

13 March 2002

Enquiries:         UK Media                                     Martin Sutton              [phone]

                                                                Philip Thomson             [phone]

                                                                Alan Chandler              [phone]

                   US Media                                     Nancy Pekarek              [phone]

                                                                Patty Seif                 [phone]

                   European Analyst / Investor                  Duncan Learmouth           [phone]
                                                                Anita Kidgell              [phone]

                   US Analyst / Investor                        Frank Murdolo              [phone]

                                                                Tom Curry                  [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange